Ginkgo Bioworks Holdings (DNA) Free Cash Flow (2020 - 2026)
Ginkgo Bioworks Holdings posted quarterly Free Cash Flow of -$48.4 million for Q1 2026, up 18.22% year-on-year from -$40.9 million in Q1 2025, and down 1.43% on a QoQ basis from -$47.7 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) has 7 years of Free Cash Flow data on file, last reported at -$48.4 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 18.22% year-over-year to -$48.4 million; the trailing twelve-month figure through Mar 2026 stood at -$167.9 million (up 51.36% YoY), and the FY2025 full-year result was -$178.7 million, up 53.23% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$48.4 million, down from -$47.7 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$23.5 million in Q1 2022 and bottomed at -$146.8 million in Q4 2022.
- The 5-year median for Free Cash Flow is -$61.3 million (2023), against an average of -$73.5 million.
- The widest annual swing landed in 2023, when Free Cash Flow sank 368.63%; it then jumped 73.35% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$146.8 million in 2022, then surged by 58.26% to -$61.3 million in 2023, then advanced by 8.38% to -$56.1 million in 2024, then grew by 15.07% to -$47.7 million in 2025, then slipped by 1.43% to -$48.4 million in 2026.
- The last three Free Cash Flow figures came in at -$48.4 million (Q1 2026), -$47.7 million (Q4 2025), and -$31.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Ginkgo Bioworks Holdings | 542.03 Mn | 542.03 Mn | 16.38 Mn | -48.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48.37 Mn |
| Mar 31, 2026 | -48.37 Mn |
| Dec 31, 2025 | -47.68 Mn |
| Dec 31, 2025 | -47.68 Mn |
| Sep 30, 2025 | -31.61 Mn |
| Sep 30, 2025 | -31.61 Mn |
| Jun 30, 2025 | -40.29 Mn |
| Jun 30, 2025 | -40.29 Mn |
| Mar 31, 2025 | -59.14 Mn |
| Mar 31, 2025 | -59.14 Mn |
| Dec 31, 2024 | -56.15 Mn |
| Dec 31, 2024 | -56.15 Mn |
| Sep 30, 2024 | -118.59 Mn |
| Sep 30, 2024 | -118.59 Mn |
| Jun 30, 2024 | -111.42 Mn |
| Jun 30, 2024 | -111.42 Mn |
| Mar 31, 2024 | -95.97 Mn |
| Mar 31, 2024 | -95.97 Mn |
| Dec 31, 2023 | -61.28 Mn |
| Dec 31, 2023 | -61.28 Mn |
| Sep 30, 2023 | -77.93 Mn |
| Sep 30, 2023 | -77.93 Mn |
| Jun 30, 2023 | -87.07 Mn |
| Jun 30, 2023 | -87.07 Mn |
| Mar 31, 2023 | -110.03 Mn |
| Mar 31, 2023 | -110.03 Mn |
| Dec 31, 2022 | -146.80 Mn |
| Dec 31, 2022 | -146.80 Mn |
| Sep 30, 2022 | -25.21 Mn |
| Sep 30, 2022 | -25.21 Mn |
| Jun 30, 2022 | -108.98 Mn |
| Jun 30, 2022 | -108.98 Mn |
| Mar 31, 2022 | -23.48 Mn |
| Mar 31, 2022 | -23.48 Mn |
| Dec 31, 2021 | -170.66 Mn |
| Dec 31, 2021 | -170.66 Mn |
| Sep 30, 2021 | -10.67 Mn |
| Sep 30, 2021 | -10.67 Mn |
| Jun 30, 2021 | -58.95 Mn |
| Jun 30, 2021 | -58.95 Mn |
| Mar 31, 2021 | -70.07 Mn |
| Mar 31, 2021 | -70.07 Mn |
| Dec 31, 2020 | -78.75 Mn |
| Dec 31, 2020 | -78.75 Mn |